Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL19971546 | 1.00 | CA1 (0.32) | CA1CA2 | |
| SCHEMBL19975859 | 0.81 | CA1 (0.35) | CA1CA2 | |
| Hydrochloric Acid SCHEMBL19970403 | 0.80 | CA1 (0.35) | CA1CA2 | |
| Hydrochloric Acid SCHEMBL19970395 | 0.80 | CA1 (0.35) | CA1CA2 | |
| Hydrochloric Acid SCHEMBL19970399 | 0.80 | CA1 (0.35) | CA1CA2 | |
| Hydrochloric Acid SCHEMBL19970407 | 0.80 | CA1 (0.35) | CA1CA2 | |
| Hydrochloric Acid SCHEMBL19970405 | 0.80 | CA1 (0.38) | CA1CA2 | |
| Hydrochloric Acid SCHEMBL19970402 | 0.80 | CA1 (0.38) | CA1CA2 | |
| Bromide SCHEMBL19971552 | 0.80 | TLR8 (0.31) | — | |
| SCHEMBL19975880 | 0.80 | CA1 (0.37) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512604-B1 | STABLE YELLOW IMIDAZOLIUM COMPOUNDS AND METHODS FOR THEIR USE | WELLA OPERATIONS US LLC (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-3512604-A1 | STABLE YELLOW IMIDAZOLIUM COMPOUNDS AND METHODS FOR THEIR USE | Noxell Corporation (US) | 2019-07-24 | — | — | EP | disclosed |
| US-10093807-B2 | Stable yellow imidazolium compounds | NOXELL CORPORATION (US) | 2018-10-09 | — | — | US | disclosed |
| WO-2018053027-A1 | STABLE YELLOW IMIDAZOLIUM COMPOUNDS AND METHODS FOR THEIR USE | NOXELL CORPORATION (US) | 2018-03-22 | — | — | WO | disclosed |
| US-20180079907-A1 | Stable Yellow Imidazolium Compounds | WELLA OPERATIONS US, LLC | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093807-B2 | Stable yellow imidazolium compounds | IK, NDUFV1, NDUFV2 | CA1 4204/4885CA2 2356/4885 |
| US-20180079907-A1 | Stable Yellow Imidazolium Compounds | IK, NDUFV1, NDUFV2 | CA1 4204/4885CA2 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.